CD28 and neoplasm: In preclinical studies, the presence of ICOS drives CAR-T-cells into a TH17/TH1 differentiation state characterised by increased IL-17 and IL-22 production, enhanced persistence and improved anti-tumour function compared with CD28 or 41BB [64,65].